Statement of Ownership (sc 13g)
June 01 2020 - 5:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. __)*
QUALIGEN THERAPEUTICS,
INC.
(Name
of Issuer)
Common
Stock, par value $0.01
(Title
of Class of Securities)
74754R103
(CUSIP
Number)
May
22, 2020
(Date
of Event Which Requires Filing of this Statement)
Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule
13d-1(c)
¨ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section
18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
Schedule
13G
|
Page
2 of 5 Pages
|
|
|
|
|
CUSIP
NO. 74754R103
|
|
Names
of Reporting Persons
i.r.s.
identification nos. of above persons (entities only)
Sekisui Diagnostics, LLC
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
(a) ¨
(b) ¨
|
|
4.
|
Citizenship or Place of Organization
|
Delaware
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5.
|
Sole Voting Power
|
|
|
1,980,233
|
|
6.
|
Shared Voting Power
|
|
|
0
|
|
7.
|
Sole Dispositive Power
|
|
|
1,980,233
|
|
8.
|
Shared Dispositive Power
|
|
|
0
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting
Person
|
|
|
|
|
|
1,980,233
|
|
|
10.
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
|
|
|
12.
|
Type of Reporting Person (See Instructions)
|
|
|
*
|
Calculated based on an aggregate of 12,526,147 shares outstanding of the Issuer’s common
stock, as provided by the Issuer.
|
|
Schedule 13G
|
Page
3 of 5 Pages
|
|
|
|
|
CUSIP NO.
74754R103
|
|
Item 1.
(a) Name
of Issuer:
Qualigen Therapeutics, Inc.
(b) Address
of Issuer's Principal Executive Offices:
2042 Corte Del Nogal
Carlsbad, California 92011
Item 2.
(a) Name
of Person Filing:
This Schedule 13G is being filed
by Sekisui Diagnostics, LLC, a Delaware limited liability company.
(b) Address
of Principal Business Office or, if none, Residence:
1 Wall Street
Burlington, Massachusetts 01803
(c) Citizenship:
Delaware
(d) Title
of Class of Securities:
Common Stock, par
value $0.01
(e) CUSIP
Number:
74754R103
|
|
Item 3.
|
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check
whether the person filing is a:
|
|
|
(a)
|
¨
|
Broker
or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
|
|
|
|
|
|
|
|
(b)
|
¨
|
Bank
as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
|
|
|
|
|
|
|
|
(c)
|
¨
|
Insurance
company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
|
|
|
|
|
|
|
|
(d)
|
¨
|
Investment
company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
|
|
|
|
|
|
|
|
(e)
|
¨
|
An
investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
|
|
|
|
|
|
|
|
(f)
|
¨
|
An
employee benefit plan or endowment fund in accordance with §240.13d-(b)(1)(ii)(F).
|
|
|
|
|
|
|
|
(g)
|
¨
|
A
parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
|
|
|
|
|
|
|
|
(h)
|
¨
|
A
savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
|
|
|
|
|
|
|
|
(i)
|
¨
|
A
church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company
Act of 1940 (15 U.S.C. 80a-3).
|
|
Schedule 13G
|
Page
4 of 5 Pages
|
|
|
|
|
CUSIP NO.
74754R103
|
|
|
|
(j)
|
¨
|
A
non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
|
|
|
|
|
|
|
|
(k)
|
¨
|
A
group, in accordance with § 240.13d-(b)(1)(ii)(K). If filing as a non-U.S. Institution
in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
N/A
|
Provide the following information regarding
the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
|
|
(a)
|
Amount beneficially owned: 1,980,233
|
|
|
(b)
|
Percent of Class: 15.8%
|
|
|
(c)
|
Number of Shares as to which the person has:
|
(i) Sole power to vote or to direct the vote: 1,980,233
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the disposition of: 1,980,233
(iv) Shared power to dispose or to direct the disposition of: 0
|
|
Item 5.
|
Ownership
of Five Percent or Less of a Class.
|
If this statement is being filed to report the fact
that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of
securities, check the following. ¨
|
|
Item 6.
|
Ownership
of More than Five Percent on Behalf of Another Person.
|
Not applicable.
|
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported
on by the Parent Holding Company or Control Person.
|
Not applicable.
|
|
Item 8.
|
Identification
and Classification of Members of the Group.
|
Not applicable.
|
|
Item 9.
|
Notice
of Dissolution of Group.
|
Not applicable.
|
Schedule
13G
|
Page
5 of 5 Pages
|
|
|
|
|
CUSIP
NO. 74754R103
|
|
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with
or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination
under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
Sekisui Diagnostics, LLC
|
|
|
|
|
|
Date: June 1, 2020
|
By:
|
/s/
Raymond De Rise
|
|
|
|
Name: Raymond De Rise
|
|
|
|
Title: General Counsel and Chief Compliance Officer
|
Footnotes:
*Attention: Intentional misstatement or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001)
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Oct 2024 to Nov 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Nov 2023 to Nov 2024
